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Following the advent of genome sequencing, the past decade
has seen an explosion in genome-scale research projects.
Major goals of this type of work include gaining an overview
of how biological systems work, generation of useful
reagents and reference datasets, and demonstration of the
efficacy of new techniques. The typical structure of these
studies, and of the resulting manuscripts, is similar to that of
a traditional genetic screen. The major steps often include
development of reagents and/or an assay, systematic
implementation of the assay, and analysis and interpretation
of the resulting data. The analyses are usually centered on
identifying patterns or groups in the data, which can lead to
predictions regarding previously unknown or unanticipated
properties of individual genes or proteins.
So that the work is not purely descriptive - anathema in the
molecular biology literature - there is frequently some
follow-up or ‘validation’, for example, application of inde-
pendent assays to confirm the initial data, an illustration of
how the results obtained apply to some specific cellular
process, or the testing of some predicted gene functions. As
the first few display items are often schematics, example
data, clustering diagrams, networks, tables of P-values and
the like, these validation experiments usually appear circa
Figure 5 or 6 in a longer-format paper. This format is
sufficiently predominant that my colleague Charlie Boone
refers to it as “applying the formula”. I have successfully
used the formula myself for many papers.
My motivation for writing this opinion piece is that, in my
own experience, as both an author and a reviewer, the focal
point of the review process - and of the editorial decision -
seems too often to rest on the quality of the validation,
which is usually not what the papers are really about. While
it is customary for authors to complain about the review
process in general (and for reviewers to complain about the
papers they review), as a reader of such papers and a user of
the datasets, I do think there are several legitimate reasons
why our preoccupation with validation in genomic studies
deserves reconsideration.
First, single-gene experiments are a poor demonstration that
a large-scale assay is accurate. To show that an assay is
consistent with previous results requires testing a
sufficiently large collection of gold-standard examples to be
able to assess standard measures such as sensitivity, false-
positive rate and false-discovery rate. A decade ago, there
were many fewer tools and resources available; for example,
Gene Ontology (GO) did not exist before the year 2000 [1],
and many of the data analysis techniques now in common
use were unfamiliar to most biologists. Proving that one
could make accurate predictions actually required doing the
laboratory analyses. But today, many tools are in place to
make the same arguments by cross-validation, which
produces all of the standard statistics. It is also (gradually)
becoming less fashionable for molecular biologists to be
statistical Luddites.
A Ab bs st tr ra ac ct t
The individual ‘validation’ experiments typically included in papers reporting genome-scale
studies often do not reflect the overall merits of the work.
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relating to a specific process, do not describe the general
utility of a dataset. Many studies have shown (even if they
did not emphasize) that specific data types and reagents are
more valuable for the study of some things than others.
Validation experiments tend to focus on the low-hanging
fruit, for instance, functional categories that seem to be
yielding the best examples, and the largest numbers. To
minimize the ire of my colleagues, I will give an example
from my own work. Our first efforts at systematically
predicting yeast gene functions from gene-expression data
[2] resulted in more predictions relating to RNA processing
than to any other category, and Northern blots are
something even my lab can do, so these were the ones we
tested. Although we would like to think that the success at
validating predictions from other processes will also be as
high as our cross-validation predicted, laboratory validation
of predictions from only one category does not show that.
Moreover, if one is engaged in high-throughput data collec-
tion, it is possible to perform a large number of validations,
and show only those that work. It is also possible to choose
the validation experiments from other screens already in
progress, or already done, or even from other labs. I suspect
this practice may be widespread.
A third issue is that focus on the validation is often at the
expense of a thorough evaluation of the key points of the
remainder of the paper. I may be further ruffling the fur of
my colleagues here, but I think it is fair to say that a
hallmark of the functional genomics/systems biology/
network analysis literature is an emphasis on artwork and
P-values, and perhaps not enough consideration of
questions such as the positive predictive value of the large-
scale data. David Botstein has described certain findings as
“significant, but not important” - if one is making millions
of measurements, an astronomically significant statistical
relationship can be obtained between two variables that
barely correlate, and an overlap of only one or a few percent
in a Venn diagram can be very significant by the widely used
hypergeometric test. A good yarn seems to distract us from a
thorough assessment of whether statistical significance
equates to biological significance, and even whether the
main dataset actually contains everything that is claimed.
I’m writing for an issue of Journal of Biology that is about
how to make the peer review process easier, but I do believe
that papers in our field would be better if referees were
allowed and expected (and given time) to look at the
primary data, have a copy of the software, use the same
annotation indices, and so on, and see whether they can
verify the claims and be confident in conclusions that are
reached from computational analyses. Even simple reality
checks such as comparing replicates (when there are some)
are often ignored by both authors and reviewers. I bring this
up because one of the major frustrations expressed by a group
of around 30 participants at the Computational and Statistical
Genomics workshop I attended at the Banff International
Research Station last June was the difficulty of reproducing
computational analyses in the functional genomics literature.
Often, the trail from the primary data to the published dataset
is untraceable, let alone the downstream analyses.
Fourth, and finally, the individual validation experiments
may not garner much attention, unless they are mentioned
in the title, or have appropriate keywords in the abstract.
They are rarely as useful as they would be in a paper in
which they were explored in more depth and in which the
individual hypothesis-driven experiments could be sum-
marized. For instance, a paper we published in Journal of
Biology in 2004 [3] described an atlas of gene expression in
55 mouse tissues and cell types. Using SVM (Support Vector
Machine) cross-validation scores, we found that, for many
GO annotation categories, it was possible to predict which
genes were in the category, to a degree that is orders of
magnitude better than random guessing, although usually
still far from perfect. The most interesting aspect of the
study to me was the observation that there is a quantitative
relationship between gene expression and gene function;
not that this was completely unexpected, but it is nice to
have experimental evidence to support the generality of
one’s assumptions. The SVM scores were used mainly to
prove the general point, and whether any individual
predictions were correct was not the key finding - we knew
ahead of time (from the cross-validation results) that most
of the individual predictions would not be correct; this is
the nature of the business. Nonetheless, final acceptance of
the manuscript hinged on our being able to show that the
predictions are accurate, so at the request of reviewers and
editors, we showed that Pwp1 is involved in rRNA
biogenesis, as predicted. According to Google Scholar, this
paper now has 139 citations, and my perusal of all of them
suggests that neither Pwp1 nor ribosome biogenesis is the
topic of any of the citing papers. The vast majority of
citations are bioinformatics analyses, reviews, and other
genomics and proteomics papers, many of them concerning
tissue-specific gene expression. Thus, the initial impact
appears primarily to have been the proof-of-principle
demonstration of the relationship between gene function
and gene expression across organs and cell types, and the
microarray data themselves. It is the use of genome-scale
data and cross-validation that proves the point, not the
individual follow-up experiments.
A small survey of my colleagues suggests that many such
examples would be found in a more extensive analysis of
the literature in functional genomics and systems biology.
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Journal of Biology 2009, 8 8: :3For instance, Jason Moffat explained that in the reviews of his
2006 Cell paper describing the RNAi Consortium lentivirus
collection [4], which already contained a screen for alteration
of the mitotic index in cultured cells, a major objection was
that more work was needed to validate the reagents by
demonstrating that the screen would also work in primary
cell cultures - which may be true, but so far, even the mitotic
index screen seems to have served primarily as an example of
what one can do with the collection. The paper has clearly
had a major impact: it has 161 citations according to Google
Scholar, the vast majority of which relate to use of the RNAi
reagents, not any of the individual findings in this paper.
To conclude, I would propose that, as authors, reviewers and
editors, we should re-evaluate our notion of what parts of
genome-scale studies really are interesting to a general
audience, and consider carefully which parts of papers prove
the points that are being made. It is, of course, important that
papers are interesting to read, have some level of independent
validation, and a clear connection to biology. But it seems
likely that pioneering reagent and data collections,
technological advances, and studies proving or refuting
common perceptions will continue to be influential and of
general interest, judging by citation rates. As erroneous data
or poorly founded conclusions could have a proportionally
detrimental influence, we should be making an effort to
scrutinize more deeply what is really in the primary data,
rather than waiting to work with it once it is published.
Conversely, the individual ‘validation’ studies that occupy the
nethermost figures, although contributing some human
interest, may be a poor investment of resources, making
papers unnecessarily long, delaying the entry of valuable
reagents and datasets into the public domain, and possibly
distracting from the main message of the manuscript.
R Re ef fe er re en nc ce es s
1. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM,
Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP,
Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE,
Ringwald M, Rubin GM, Sherlock G: G Ge en ne e   o on nt to ol lo og gy y: :   t to oo ol l   f fo or r   t th he e
u un ni if fi ic ca at ti io on n   o of f   b bi io ol lo og gy y. .   T Th he e   G Ge en ne e   O On nt to ol lo og gy y   C Co on ns so or rt ti iu um m. .   Nat Genet
2000, 2 25 5: :25-29.
2. Wu LF, Hughes TR, Davierwala AP, Robinson MD, Stoughton R,
Altschuler SJ: L La ar rg ge e- -s sc ca al le e   p pr re ed di ic ct ti io on n   o of f   S Sa ac cc ch ha ar ro om my yc ce es s   c ce er re ev vi is si ia ae e
g ge en ne e   f fu un nc ct ti io on n   u us si in ng g   o ov ve er rl la ap pp pi in ng g   t tr ra an ns sc cr ri ip pt ti io on na al l   c cl lu us st te er rs s. . Nat Genet
2002, 3 31 1: :255-265.
3. Zhang W, Morris QD, Chang R, Shai O, Bakowski MA, Mitsakakis
N, Mohammad N, Robinson MD, Zirngibl R, Somogyi E, Laurin N,
Eftekharpour E, Sat E, Grigull J, Pan Q, Peng WT, Krogan N,
Greenblatt J, Fehlings M, van der Kooy D, Aubin J, Bruneau BG,
Rossant J, Blencowe BJ, Frey BJ, Hughes TR: T Th he e   f fu un nc ct ti io on na al l   l la an nd d- -
s sc ca ap pe e   o of f   m mo ou us se e   g ge en ne e   e ex xp pr re es ss si io on n. . J Biol 2004, 3 3: :21.
4. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G,
Piqani B, Eisenhaure TM, Luo B, Grenier JK, Carpenter AE, Foo
SY, Stewart SA, Stockwell BR, Hacohen N, Hahn WC, Lander ES,
Sabatini DM, Root DE: A A   l le en nt ti iv vi ir ra al l   R RN NA Ai i   l li ib br ra ar ry y   f fo or r   h hu um ma an n   a an nd d
m mo ou us se e   g ge en ne es s   a ap pp pl li ie ed d   t to o   a an n   a ar rr ra ay ye ed d   v vi ir ra al l   h hi ig gh h- -c co on nt te en nt t   s sc cr re ee en n. . Cell
2006, 1 12 24 4: :1283-1298.
http://jbiol.com/content/8/1/3 Journal of Biology 2009, Volume 8, Article 1 Hughes 3.3
Journal of Biology 2009, 8 8: :3